Table 1 Patients characteristics between ultrahypo fractionated radiotherapy and brachytherapy with or without external beam radiotherapy.

From: Comparison of toxicities between ultrahypofractionated radiotherapy versus brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer

Variables

Group

UHF (n = 253)

Subgroup of UHF

BT ± EBRT (n = 1664)

Subgroup of BT ± EBRT

p-value*

L-UHF (n = 162)

H-UHF (n = 91)

HDR + EBRT (n = 1187)

LDR (n = 411)

LDR + EBRT (n = 66)

Age

 

72.00 [54.00, 86.00]

72.00 [54.00, 86.00]

73.00 [54.00, 86.00]

69.00 [42.00, 86.00]

70.00 [42.00, 86.00]

69.00 [45.00, 83.00]

68.00 [52.00, 79.00]

 < 0.001

iPSA (mg/ml)

 

8.12 [1.70, 188.00]

7.81 [1.70, 87.60]

9.60 [3.90, 188.00]

10.70 [1.40, 3208.00]

14.72 [2.68, 3208.00]

6.80 [1.40, 26.00]

7.94 [3.20, 46.00]

 < 0.001

T (%)

T1

97 (38.3)

69

28

472 (28.4)

240 (20.2)

220 (53.5)

12 (18.2)

 < 0.001

T2

131 (51.8)

86

45

641 (38.5)

407 (34.3)

191 (46.5)

43 (65.2)

 

T3

25 ( 9.9)

7

18

551 (33.1)

540 (45.5)

0 ( 0.0)

11 (16.7)

 

GS (%)

 ≤ 6

56 (22.1)

44 (27.2)

12 (13.2)

373 (22.4)

101 ( 8.5)

263 (64.0)

9 (13.6)

0.003

7

140 (55.3)

91 (56.2)

49 (53.8)

741 (44.5)

560 (47.2)

148 (36.0)

33 (50.0)

 

8 ≤ 

57 (22.5)

27 (16.7)

30 (33.0)

550 (33.1)

526 (44.3)

0 ( 0.0)

24 (36.4)

 

NCCN (%)

High

67 (26.5)

30 (19.6)

37 (37.0)

939 (56.5)

901 (76.1)

2 ( 0.5)

36 (54.5)

 < 0.001

Intermediate

153 (60.5)

104 (64.2)

49 (53.8)

519 (31.2)

272 (23.0)

217 (52.8)

30 (45.5)

 

Low

33 (13.0)

28 (17.3)

5 ( 5.5)

203 (12.2)

11 ( 0.9)

192 (46.7)

0 ( 0.0)

 

Follow-up periods

(Months)

32.00 [22.00, 97.00]

30.70 [22.00, 97.00]

36.00 [24.00, 77.00]

75.00 [22.00, 177.00]

69.00 [22.00, 177.00]

91.00 [29.00, 169.00]

78.00 [30.00, 148.00]

 < 0.001

ADT (%)

Yes

149 (58.9)

83 (51.2)

66 (72.5)

1524 (91.6)

1134 (95.5)

330 (80.3)

60 (90.9)

 < 0.001

No

104 (41.1)

79 (48.8)

25 (27.5)

140 ( 8.4)

53 ( 4.5)

81 (19.7)

6 ( 9.1)

 

Total ADT duration

(Months)

12.00 [2.00, 51.00]

2.50 [2.00, 48.00]

8.00 [2.00, 51.00]

32.00 [1.00, 112.00]

43.00 [1.00, 112.00]

6.00 [1.00, 24.00]

4.00 [1.00, 24.00]

0.002

Neo ADT (%)

Yes

143 (56.5)

77 (47.5)

66 (72.5)

1516 (91.1)

1127 (94.9)

329 (80.0)

60 (90.9)

 < 0.001

No

110 (43.5)

85 (52.5)

25 (27.5)

148 ( 8.9) |

60 ( 5.1)

82 (20.0)

6 ( 9.1)

 

Neo. duration

(Months)

6.00 [1.00, 48.00]

6.00 [1.00, 48.00]

6.00 [3.00, 24.00]

8.00 [1.00, 92.00]

11.00 [1.00, 92.00]

6.00 [1.00, 24.00]

4.00 [1.00, 13.00]

 < 0.001

Adjuvant ADT (%)

Yes

81 (32.0)

41 (25.3)

40 (44.0)

1089 (65.4)

1134 (95.5)

330 (80.3)

60 (90.9)

 < 0.001

No

172 (68.0)

121 (74.7)

51 (56.0)

575 (34.6)

53 ( 4.5)

81 (19.7)

6 ( 9.1)

 

Adjuvant duration

(months)

18.00 [1.00, 39.00]

1.00 [3.00, 30.00]

24.00 [1.00, 39.00]

36.00 [1.00, 93.00]

36.00 [1.00, 93.00]

3.00 [1.00, 9.00]

3.00 [1.00, 19.00]

 < 0.001

  1. Bold values indicate statistically significance.
  2. *p-value was calculated between UHF and BT ± EBRT.
  3. BT brachytherapy, EBRT external beam radiotherapy, UHF ultrahypofractionated radiotherapy, L-UHF low dose UHF EQD2 < 100 Gy1.5 (α/β = 1.5), H-UHF high dose UHF EQD2 ≥ 100 Gy1.5 (α/β = 1.5).
Back to article page